findmyKOL

John Leonard, MD

Enriched profile

Chief, Division of Hematology and Medical Oncology & Director, Center for Blood Cancers, Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology, NYU Grossman School of Medicine · NYU Langone Health

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyHematology / OncologyFocusLymphoma Diagnosis and Treatment+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceverified 2026Payments2021–2025NIH funding1998–2008Why? →

John Leonard is Chief, Division of Hematology and Medical Oncology & Director, Center for Blood Cancers, Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology, NYU Grossman School of Medicine at NYU Langone Health. OpenAlex indexes 818 publications with 32,192 citations (h-index 86); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

John Leonard, MD, is Chief, Division of Hematology and Medical Oncology & Director, Center for Blood Cancers, Perlmutter Cancer Center at NYU Langone Health / NYU Grossman School of Medicine (Perlmutter Cancer Center). The public record shows 818 publications with 32,192 citations (h-index 86), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 25 companies, 4 NIH-funded awards (1998–2008).

  • Top research focus: Lymphoma Diagnosis and Treatment
  • 12 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 25 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma10 trialsHodgkin Disease3 trialsLeukemia (AML/ALL/CML/CLL)2 trialsLeukemia, Lymphocytic, Chronic, B-Cell2 trialsLeukemia, Lymphoid2 trialsLymphoma, Non-Hodgkin1 trialLymphoma, Large-Cell, Anaplastic1 trialLymphoma, Follicular1 trialMultiple Sclerosis1 trialLymphoma, Large B-Cell, Diffuse1 trialLymphoma, B-Cell1 trial

Research focus

OpenAlex concept fingerprint
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchViral-associated cancers and disordersCNS Lymphoma Diagnosis and Treatment

Drugs & molecules

across trials, industry payments and publications
Adcetrisgeneric · Brentuximab vedotinClinical trialsIndustry payments4Publications1Rituxangeneric · RituximabClinical trialsIndustry payments1Publications3Calquencegeneric · AcalabrutinibClinical trialsIndustry payments11Publications

Works with

trial sponsors and companies reporting payments
Seagen Inc.Clinical trials1Industry payments2Genentech, Inc.Clinical trialsIndustry payments23AstraZeneca UK LimitedClinical trialsIndustry payments9

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
818publications

Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.

32,192citations

Total citations across indexed works.

86h-index

Hirsch index (OpenAlex). i10-index 347.

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials
25companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 1998–2008

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    100%
    Short-acting sulfonamides100%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
Where care is delivered (Part B)15.7% facility · 84.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

4 NIH research awards on record, funded 19982008 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

159 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Spotify

    open.spotify.com/show/6MQnPwZIXJHrCVBBxhTt37

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com
  • X / Twitter

    x.com/JohnPLeonardMD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
  • ResearchGate

    researchgate.net/scientific-contributions/John-Leonard-2086708445

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    onclive.com/authors/john-p-leonard-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com
  • X / Twitter

    NYU Langone official announcement of appointment posted on X (@nyulangone)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org
  • Board Certified

    Hematology, American Board of Internal Medicine

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org
  • MD

    University of Virginia School of Medicine

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org

Editorial & leadership roles

journal and society appointments
  • Member

    Board of Directors, Lymphoma Research Foundation

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org
  • Past Chair

    Scientific Advisory Board, Lymphoma Research Foundation

    2015
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lymphoma.org
  • Chair

    Lymphoma Committee, Alliance for Clinical Trials in Oncology (National Cancer Institute)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.weill.cornell.edu
4 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.